Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations
- PMID: 37467493
- PMCID: PMC11016351
- DOI: 10.1021/acsbiomaterials.3c00651
Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations
Abstract
The manufacturing process of chimeric antigen receptor T cell therapies includes isolation systems that provide pure T cells. Current magnetic-activated cell sorting and immunoaffinity chromatography methods produce desired cells with high purity and yield but require expensive equipment and reagents and involve time-consuming incubation steps. Here, we demonstrate that aptamers can be employed in a continuous-flow resin platform for both depletion of monocytes and selection of CD8+ T cells from peripheral blood mononuclear cells at low cost with high purity and throughput. Aptamer-mediated cell selection could potentially enable fully synthetic, traceless isolations of leukocyte subsets from a single isolation system.
Keywords: CAR T cell manufacturing; aptamers; cell isolation; chromatography.
Conflict of interest statement
Competing Interests
Michael Jensen has interests in Umoja Biopharma and Juno Therapeutics, a Bristol-Myers Squibb company. Michael Jensen is a seed investor and holds ownership equity in Umoja, serves as a member of the Umoja Joint Steering Committee, and is a Board Observer of the Umoja Board of Directors. Michael Jensen holds patents, some of which are licensed to Umoja Biopharma and Juno Therapeutics.
Figures




Similar articles
-
Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.Acc Chem Res. 2020 Sep 15;53(9):1724-1738. doi: 10.1021/acs.accounts.0c00335. Epub 2020 Aug 6. Acc Chem Res. 2020. PMID: 32786336
-
Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy.Nat Biomed Eng. 2019 Oct;3(10):783-795. doi: 10.1038/s41551-019-0411-6. Epub 2019 Jun 17. Nat Biomed Eng. 2019. PMID: 31209354 Free PMC article.
-
An innovative cascade system for simultaneous separation of multiple cell types.PLoS One. 2013 Sep 6;8(9):e74745. doi: 10.1371/journal.pone.0074745. eCollection 2013. PLoS One. 2013. PMID: 24040334 Free PMC article.
-
Better by design: What to expect from novel CAR-engineered cell therapies?Biotechnol Adv. 2022 Sep;58:107917. doi: 10.1016/j.biotechadv.2022.107917. Epub 2022 Feb 9. Biotechnol Adv. 2022. PMID: 35149146 Review.
-
Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies.Life Sci. 2022 Nov 15;309:121016. doi: 10.1016/j.lfs.2022.121016. Epub 2022 Sep 28. Life Sci. 2022. PMID: 36179813 Review.
References
-
- Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri K. v.; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine 2017, 377 (26), 2531–2544. DOI: 10.1056/NEJMoa1707447. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials